Progress on the treatment of oligometastatic prostate cancer
10.3760/cma.j.cn112330-20230314-00080
- VernacularTitle:寡转移前列腺癌的治疗进展
- Author:
Minghuan LI
1
;
Jiasheng BIAN
Author Information
1. 山东省肿瘤防治研究院 山东第一医科大学附属肿瘤医院放疗科，济南 250117
- Keywords:
Prostatic neoplasms;
Carcinoma;
Oligometastasis;
Systemic therapy;
Local therapy
- From:
Chinese Journal of Urology
2024;45(7):559-562
- CountryChina
- Language:Chinese
-
Abstract:
Patients with oligometastatic prostate cancer based on accurate diagnosis should be given active treatment. We should optimize the benefit through tailored approaches encompassing systemic treatment, local therapy, and metastasis-directed therapy. The optimal combination and duration of systemic treatment are currently undefined. Combining new hormonal agents with androgen deprivation therapy is recommended. Most experts advocate a duration of hormonal therapy ranging from 18 to 36 months. Local therapy for the primary lesion, surgery or radiotherapy, has been clinically validated for its feasibility and effectiveness in oligometastatic prostate cancer patients. Stereotactic ablative radiation therapy for metastatic lesions ensures safe and reliable local control. In summary, maximal eradication of all visible active lesions may confer a survival benefit to these patients. We provide a comprehensive review for the treatment of oligometastatic hormone-sensitive prostate cancer, aiming to contribute insights for clinical diagnosis and treatment.
